Neurocrine Posts KINECT-PRO Data as Revenue Jumps 39%

EarningsProduct / TechM&A · Partnership
โดย Insider Monkey·US·Read original
Summary · why it matters

Neurocrine Biosciences on August 12 published KINECT-PRO Phase 4 findings showing INGREZZA eased the daily burden of tardive dyskinesia beyond what clinician rating scales capture. The study followed 59 tardive dyskinesia patients on daily INGREZZA for 24 weeks, with 52 reaching the final visit; among the 45 patients in the efficacy analysis, about 58% hit the threshold for symptomatic remission on clinician-rated movement severity, with gains exceeding the clinically meaningful threshold by Week 4 on movement severity and by Week 8 on patient-reported impact. The data landed weeks after Neurocrine's July 30 second-quarter report, which showed total revenue up 39% year over year to $959 million and INGREZZA sales climbing 15% to $716 million on record new prescriptions, prompting management to raise full-year INGREZZA guidance to $2.825 billion to $2.875 billion. CRENESSITY and the newly acquired VYKAT XR added $184 million and $54 million respectively. The growth came at a cost: cash and marketable securities fell from roughly $2.5 billion at the end of 2025 to about $482 million by June 30, largely because Neurocrine paid $53.00 a share in cash to acquire Soleno Therapeutics in a $2.9 billion deal that closed in May, backstopped by a new $1.0 billion revolving credit facility. Second-quarter R&D rose to $327 million from $244 million a year earlier, SG&A jumped to $440 million from $286 million, and the Soleno deal added roughly $2.2 billion of intangible assets that will amortize over 16 years, while INGREZZA still supplied about three-quarters of quarterly revenue.

Impact on stocks 2

Biotech & Genomic Medicine▲ · 2 stocks
Neurocrine Biosciences Inc
NBIX
▲ PositiveCapitalTechnologyrelevance

Q2 revenue rose 39% to $959M with INGREZZA sales up 15% to $716M, prompting raised full-year INGREZZA guidance.

Soleno Therapeutics Inc
SLNO
± MixedCapitalrelevance

Soleno was acquired by Neurocrine for $53.00/share cash in a $2.9B deal that closed in May; mentioned only as the acquisition target.

Theme Impact 1

Related news

Axsome Therapeutics Reports New Clinical Data in Depression and Alzheimer's Agitation

Axsome Therapeutics reported new clinical data in major depressive disorder and Alzheimer's disease agitation at a leading psychiatry congress. The presentations focused on key programs in Axsome's central nervous system pipeline aimed at treating mood and neuropsychiatric symptoms, and management highlighted how the new findings may inform future study designs and regulatory interactions for these indications. The company is advancing multiple late-stage clinical programs, including AXS-05, AXS-12, AXS-14, and several solriamfetol indications, and the fresh congress results give more clinical detail around AXS-05 in depression and Alzheimer's agitation, feeding the thesis that future CNS indications can broaden the revenue mix beyond Auvelity, Sunosi and SYMBRAVO. Axsome, a mid-sized US pharmaceuticals player with a market cap of $11.2b, competes alongside larger CNS-focused drug developers such as Biogen and Eli Lilly and smaller specialists. The same update also stress tests a key risk: management must commercialise several CNS assets at once while running high R&D and SG&A spending, with payer scrutiny and strong rivals in both categories.
AXSM ▲
Biotech & Genomic Medicine
Simply Wall St·3hRead more →
▲2

Novartis Acquires Full Rights to Sironax Brain Delivery Platform

Novartis agreed to acquire full rights to Sironax's proprietary brain delivery platform for neurological disease treatments. The deal gives Novartis control of Sironax's technology designed to transport therapeutics across the blood brain barrier, expanding its toolkit for research into central nervous system disorders where treatment options remain limited. Novartis is a large pharmaceuticals group with a CHF218.8 billion market cap that researches, develops, manufactures, distributes, markets, and sells medicines globally, so gaining access to differentiated delivery technology directly links into its existing focus on complex neurological treatments. The Sironax platform speaks to the same advanced-therapy thesis that underpins Cosentyx's CHMP progress and remibrutinib's Phase 3 data, as Novartis seeks to own hard-to-reach biology where rivals like Roche and Biogen also compete for neurologists' attention. The flip side is that every new modality adds complexity, and recent trial setbacks such as pelacarsen and del-desiran keep development risk front and center, with analysts flagging that stacking capital-intensive projects on top of share buybacks could stretch the balance sheet of a business already carrying a high level of debt.
NOVN.SW ▲
Biotech & Genomic Medicine ▲
Simply Wall St·4hRead more →
2

AbbVie Unveils New VRAYLAR Real-World and Pediatric Safety Data at Psych Congress 2026

AbbVie shared new real-world and pediatric safety data for VRAYLAR in major depressive disorder and bipolar I at Psych Congress 2026. The findings covered routine clinical practice settings, including patients with complex comorbidities and underserved groups, while the pediatric data added information on safety and use in younger patients with mood disorders. AbbVie, a research-focused biopharmaceutical group with a US$466.6b market cap, positions VRAYLAR within a broad portfolio targeting chronic conditions including complex psychiatric disorders. The company said the next concrete checkpoint will be how these data feed into prescribing and label use over the next year, particularly uptake of newly approved low dose VRAYLAR in pediatric and adjunctive MDD settings, trackable in reported prescription trends and segment sales through 2027.
ABBV ▲
Biotech & Genomic Medicine
Simply Wall St·4hRead more →
© 2026 MarketDXNews